GAL-101

Product Description

MRZ-99030 (now GAL-101) is a proprietary compound designed to prevent the formation of all forms of toxic amyloid beta oligomers, by binding with high affinity to the misfolded amyloid beta monomers, but not to the normally folded version, before they can form toxic soluble oligomers.Ê These then rapidly conglomerate into amorphous, non-beta-sheet formations, which we call Òblobs.ÓÊ These ÒblobsÓ are innocuous and are thought to be cleared by the circulation. (Sourced from: https://www.galimedix.com/news-media/press-releases/detail/5/new-in-vitro-study-demonstrates-galimedix-therapeutics)

Mechanisms of Action: AB Modulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merz
Company Location:
Company CEO:
Additional Commercial Interests: None